Cara Tannenbaum

Tannenbaum completed medical school (1994), additional training in geriatrics (2000), and a Master of Science degree in epidemiology and biostatistics (2002) at McGill University.{{Cite web|url=https://recherche.umontreal.ca/english/our-researchers/professors-directory/researcher/is/in14616/|title=Researcher|website=La recherche - Université de Montréal|language=en|access-date=2020-01-04}}{{Cite web|url=https://medecine.umontreal.ca/recherche/les-chercheurs-de-la-faculte/portraits-chercheurs/cara-tannenbaum-oser-vieillir-sante/|title=Cara Tannenbaum : oser vieillir en santé - Faculté de médecine - Université de Montréal|website=Faculté de médecine|language=fr-FR|access-date=2020-01-04}}{{Cite web|title=Tannenbaum Cara|url=https://criugm.qc.ca/en/chercheurs/tannenbaum-cara-en/|access-date=2022-01-08|website=CRIUGM|language=en}} She is now a professor of medicine and pharmacy at the Université de Montréal, where she conducts research at the Centre de recherche de l’Institut universitaire de gériatrie de Montréal.{{Cite web|title=Tannenbaum Cara|url=https://criugm.qc.ca/en/chercheurs/tannenbaum-cara-en/|access-date=2022-01-08|website=CRIUGM|language=en}}{{Cite web|url=https://cihr-irsc.gc.ca/e/50878.html|title=Biography – IGH Scientific Director: Dr. Cara Tannenbaum - CIHR|last=Government of Canada|first=Canadian Institutes of Health Research|date=2011-06-29|website=cihr-irsc.gc.ca|access-date=2020-01-04}}{{Cite web|url=https://nouvelles.umontreal.ca/en/article/2018/11/13/want-to-cut-down-on-your-meds-your-pharmacist-can-help/|title=Want to cut down on your meds? Your pharmacist can help.|last=|first=|date=2019-07-15|website=nouvelles.umontreal.ca|language=en|url-status=live|archive-url=https://web.archive.org/web/20190131172543/https://nouvelles.umontreal.ca/en/article/2018/11/13/want-to-cut-down-on-your-meds-your-pharmacist-can-help/ |archive-date=2019-01-31 |access-date=2020-01-04}}{{Cite web|url=https://www.pharmaceutical-journal.com/news-and-analysis/features/deprescribing-the-fightback-against-polypharmacy-has-begun/20205686.article|title=Deprescribing: the fightback against polypharmacy has begun|last=Pike|first=Harriet|date=|website=The Pharmaceutical Journal|language=en|url-status=live|archive-url=https://web.archive.org/web/20200910053544/https://www.pharmaceutical-journal.com/news-and-analysis/features/deprescribing-the-fightback-against-polypharmacy-has-begun/20205686.article |archive-date=2020-09-10 |access-date=2020-01-04}} In 2015, Tannenbaum was appointed Scientific Director of the Institute of Gender and Health at the Canadian Institutes of Health Research and was appointed Departmental Science Advisor for Health Canada in 2019.{{Cite web|last=Government of Canada|first=Canadian Institutes of Health Research|date=2011-06-29|title=Biography – IGH Scientific Director: Dr. Cara Tannenbaum - CIHR|url=https://cihr-irsc.gc.ca/e/50878.html|access-date=2022-01-08|website=cihr-irsc.gc.ca}}

Tannenbaum was initially involved in the EMPOWER (Eliminating Medications Through Patient Ownership of End Results) trial, which is an educational intervention (using a theory-based patient handout) to engage older adults with their pharmacist or physician in discontinuing inappropriate medication.{{Cite web|url=https://clinicaltrials.gov/ct2/show/NCT01148186|title=An Intervention Study to Reduce the Use and Impact of Potentially Inappropriate Medications Among Older Adults - Full Text View - ClinicalTrials.gov|website=clinicaltrials.gov|language=en|access-date=2020-01-04}}{{Cite journal|last1=Martin|first1=Philippe|last2=Tannenbaum|first2=Cara|date=2017-04-01|title=A realist evaluation of patients' decisions to deprescribe in the EMPOWER trial|journal=BMJ Open|language=en|volume=7|issue=4|pages=e015959|doi=10.1136/bmjopen-2017-015959|issn=2044-6055|pmid=28473524|pmc=5566584}} The EMPOWER trial resulted in 27% of participants in the intervention group discontinuing their benzodiazepine use (compared with 5% of the control group) at six months.{{Cite journal|last1=Tannenbaum|first1=Cara|last2=Martin|first2=Philippe|last3=Tamblyn|first3=Robyn|last4=Benedetti|first4=Andrea|last5=Ahmed|first5=Sara|date=2014-06-01|title=Reduction of Inappropriate Benzodiazepine Prescriptions Among Older Adults Through Direct Patient Education: The EMPOWER Cluster Randomized Trial|journal=JAMA Internal Medicine|language=en|volume=174|issue=6|pages=890–898|doi=10.1001/jamainternmed.2014.949|pmid=24733354|issn=2168-6106|doi-access=free}} Through this trial, Tannenbaum and her colleagues found that two-thirds of individuals who received EMPOWER handouts had taken it to their doctor or pharmacist, but in about half of these instances, the health care professionals discouraged deprescribing. This prompted Tannenbaum to launch and oversee the D-PRESCRIBE clinical trial, which tested whether a pharmacist-led educational intervention could decrease the number of prescriptions issued for inappropriate medication among 489 older adults in Quebec.{{Cite journal|last1=Martin|first1=Philippe|last2=Tamblyn|first2=Robyn|last3=Benedetti|first3=Andrea|last4=Ahmed|first4=Sara|last5=Tannenbaum|first5=Cara|date=2018-11-13|title=Effect of a Pharmacist-Led Educational Intervention on Inappropriate Medication Prescriptions in Older Adults: The D-PRESCRIBE Randomized Clinical Trial|journal=JAMA|language=en|volume=320|issue=18|pages=1889–1898|doi=10.1001/jama.2018.16131|pmid=30422193|pmc=6248132|issn=0098-7484|doi-access=free}}{{Cite news|url=https://www.nytimes.com/2019/01/28/upshot/pharmacists-drugs-health-unsung-role.html|title=The Unsung Role of the Pharmacist in Patient Health|last=Carroll|first=Aaron E.|date=2019-01-28|work=The New York Times|access-date=2020-01-04|language=en-US|issn=0362-4331}} The trial found that a pharmacist intervention resulted in greater medication discontinuation (43%) at six months than those receiving regular care.

Between May 2013 and July 2017, Tannenbaum led the international "Dare to Age Well for Women" urinary incontinence trial (also referred to as the CACTUS-D i.e. Continence Across Continents To Upend Stigma and Dependency), which was a randomised controlled trial to test the effect of a continence promotion intervention on the urinary symptoms and quality of life in 910 women, aged 65 or older, in the United Kingdom, France, and Canada (Alberta, Quebec).{{Cite web|url=https://clinicaltrials.gov/ct2/show/NCT01858493|title=Continence Across Continents to Upend Stigma and Dependency - Full Text View - ClinicalTrials.gov|website=clinicaltrials.gov|language=en|access-date=2020-01-04}}{{Cite journal|last1=Tannenbaum|first1=Cara|last2=van den Heuvel|first2=Eleanor|last3=Fritel|first3=Xavier|last4=Southall|first4=Kenneth|last5=Jutai|first5=Jeffrey|last6=Rajabali|first6=Saima|last7=Wagg|first7=Adrian|date=December 2015|title=Continence Across Continents To Upend Stigma and Dependency (CACTUS-D): study protocol for a cluster randomized controlled trial|journal=Trials|language=en|volume=16|issue=1|pages=565|doi=10.1186/s13063-015-1099-x|issn=1745-6215|pmc=4676178|pmid=26652168 |doi-access=free }}{{Cite web|url=https://eoa.umontreal.ca/2012/11/08/2424/|title=Cara Tannenbaum et Jean-Pierre Gagné au cœur des six projets 2012 retenus par l'ERA-AGE - École d'orthophonie et d'audiologie - Université de Montréal|date=2012-11-08|website=École d'orthophonie et d'audiologie|language=fr-FR|access-date=2020-01-04}} So far, results from the women recruited from the UK indicate that participants in the combined intervention group had the highest rate of urinary symptom improvement, and that the recruitment rate for local community organizations was as high as 44%.{{Cite journal|last1=Tannenbaum|first1=Cara|last2=Agnew|first2=Rona|last3=Benedetti|first3=Andrea|last4=Thomas|first4=Doneal|last5=van den Heuvel|first5=Eleanor|date=December 2013|title=Effectiveness of continence promotion for older women via community organisations: a cluster randomised trial|journal=BMJ Open|language=en|volume=3|issue=12|pages=e004135|doi=10.1136/bmjopen-2013-004135|issn=2044-6055|pmc=3863125|pmid=24334159}}{{Cite journal|last1=Agnew|first1=Rona|last2=van den Heuvel|first2=Eleanor|last3=Tannenbaum|first3=Cara|date=February 2013|title=Efficiency of using community organisations as catalysts for recruitment to continence promotion trials|journal=Clinical Trials: Journal of the Society for Clinical Trials|language=en|volume=10|issue=1|pages=151–159|doi=10.1177/1740774512460144|pmid=23043154|s2cid=20884658|issn=1740-7745|url=http://bura.brunel.ac.uk/handle/2438/8961}}

Tannenbaum co-founded the Canadian Deprescribing Network (CaDeN), and previously served as a co-director.{{Cite web|title=Tannenbaum Cara|url=https://criugm.qc.ca/en/chercheurs/tannenbaum-cara-en/|access-date=2022-01-08|website=CRIUGM|language=en}}

During the COVID-19 pandemic, Tannenbaum has served on the Canada Chief Science Advisor's Expert Group on Health Systems, and helped lead the implementation efforts for CanCOVID, a Canada-wide network of over 3,000 health, science and policy researchers to facilitate COVID-19 research collaboration.{{Cite web|last=Government of Canada|first=Innovation|title=Expert Group on Health Systems - Science.gc.ca|url=https://science.gc.ca/eic/site/063.nsf/eng/h_98017.html|access-date=2022-01-08|website=science.gc.ca}}{{Cite web|last=Government of Canada|first=Innovation|title=CanCOVID Network - Science.gc.ca|url=https://science.gc.ca/eic/site/063.nsf/eng/h_98020.html|access-date=2022-01-08|website=science.gc.ca}}{{Cite web|last=Digital|first=Rocket|title=Trailblazer Award Winner|url=https://sciencepolicy.ca/conference/cspc-2020/trailblazer-award-winner/|access-date=2022-01-08|website=CSPC|language=en-CA}} With Holly Witteman and Jenna Haverfield, Tannenbaum found that when the Canadian Institutes of Health Research implemented data-driven gender policy interventions in a second COVID-19 funding competition (April-May 2020), the funding competition received more grant applications from female scientists, and received and funded more grant applications which considered sex and gender in their study design.{{Cite journal|last1=Witteman|first1=Holly O.|last2=Haverfield|first2=Jenna|last3=Tannenbaum|first3=Cara|date=2021-02-09|title=COVID-19 gender policy changes support female scientists and improve research quality|journal=Proceedings of the National Academy of Sciences of the United States of America|volume=118|issue=6|pages=e2023476118|doi=10.1073/pnas.2023476118|issn=0027-8424|pmc=8017703|pmid=33531366|bibcode=2021PNAS..11820234W|doi-access=free }}

Tannenbaum has published over 200 academic publications, which have been cited over 6,500 times, resulting in a h-index and i10-index of 42 and 101 respectively.{{Cite web|title=Cara Tannenbaum|url=https://scholar.google.ca/citations?user=FA9EbjEAAAAJ&hl=fr|access-date=2022-01-08|website=scholar.google.ca}}

In 2018, Tannenbaum was inducted as a fellow of the Canadian Academy of Health Sciences.{{Cite web|url=https://cahs-acss.ca/directory/|title=CAHS Fellows Directory – Canadian Academy of Health Sciences|language=en-US|access-date=2020-01-04}}{{Cite web|url=https://nouvelles.umontreal.ca/article/2018/09/14/deux-professeurs-de-l-udem-entrent-a-l-academie-canadienne-des-sciences-de-la-sante/|title=Deux professeurs de l'UdeM entrent à l'Académie canadienne des sciences de la santé|last=|first=|date=2018-09-14|website=nouvelles.umontreal.ca|language=fr|url-status=live|archive-url=https://web.archive.org/web/20201123165501/https://nouvelles.umontreal.ca/article/2018/09/14/deux-professeurs-de-l-udem-entrent-a-l-academie-canadienne-des-sciences-de-la-sante/ |archive-date=2020-11-23 |access-date=2020-01-04}} She has been awarded the Association of Faculties of Medicine of Canada's May-Cohen Gender Equity Award, the Canadian Institutes of Health Research's Betty Haven's Knowledge Transfer Prize in Aging, the Society of Chemical Industry Purvis Memorial Award (2020) and the American Society for Clinical Pharmacology & Therapeutics' William B. Abrams Awards in Geriatric Clinical Pharmacology (2021), and is the Michel-Saucier Endowed Chair in Geriatric Pharmacology, Health and Aging.{{Cite web|url=http://www.scientifique-en-chef.gouv.qc.ca/en/impacts-of-research-cat/gender_soigner-au-feminin/|title=Better care for women's health|website=Scientifique en chef|language=en-US|access-date=2020-01-04}}{{Cite web|url=https://deptmed.umontreal.ca/2013/08/20/prix-betty-havens-2013-de-lapplication-des-connaissances-de-linstitut-du-vieillissement-des-irsc-pour-dre-cara-tannenbaum/|title=Prix Betty-Havens 2013 de l'application des connaissances de l'Institut du vieillissement des IRSC pour Dre Cara Tannenbaum - Département de médecine - Université de Montréal|date=2013-08-20|website=Département de médecine|language=fr-FR|access-date=2020-01-04}}{{Cite web|title=Society of Chemical Industry - Purvis Memorial Award|url=https://www.soci.org/awards/past-recipients/purvis-memorial-award|access-date=2022-01-08|website=www.soci.org|language=en}}{{Cite web|title=ASCPT Awards|url=https://www.ascpt.org/Member-Services/About-ASCPT/ASCPT-Awards|access-date=2022-01-08|website=www.ascpt.org}} In 2020, Tannenbaum was awarded the Canadian Science Policy Centre's Exceptional Contribution to Science Policy Award: Trailblazer Award.{{Cite web|last=Digital|first=Rocket|title=Trailblazer Award Winner|url=https://sciencepolicy.ca/conference/cspc-2020/trailblazer-award-winner/|access-date=2022-01-08|website=CSPC|language=en-CA}}

On November 17, 2021, Tannenbaum was appointed as a Member of the Order of Canada for "her leadership in geriatrics, women’s health and gender research, and for her inter-professional collaborations to optimize healthy aging across the lifespan".{{Cite web|last=General|first=Office of the Secretary to the Governor|date=2021-12-20|title=Governor General announces 135 new appointments to the Order of Canada|url=https://www.gg.ca/en/activities/2021/governor-general-announces-135-new-appointments-order-canada|access-date=2022-01-08|website=The Governor General of Canada}}{{Cite web|title=Two dozen Quebecers appointed to the Order of Canada|url=https://montrealgazette.com/news/local-news/two-dozen-quebecers-appointed-to-the-order-of-canada|access-date=2022-01-08|website=montrealgazette|language=en-CA}}

Tannenbaum has also written editorials regarding various issues related to her research expertise, including an editorial in The BMJ to address the International Association of Athletics Federations' new "differences of sex development" rules causing Caster Semenya to no longer be eligible, and why sex and gender matter in implementation research in the BMC Medical Research Methodology.{{Cite journal|last1=Tannenbaum|first1=Cara|last2=Bekker|first2=Sheree|date=2019-03-20|title=Sex, gender, and sports|url=https://www.bmj.com/content/364/bmj.l1120|journal=BMJ|language=en|volume=364|pages=l1120|doi=10.1136/bmj.l1120|issn=0959-8138|pmid=30894351|s2cid=84843710|url-access=subscription}}{{Cite web|url=https://nouvelles.umontreal.ca/en/article/2019/03/20/when-does-a-woman-have-too-much-testosterone-when-she-s-an-athlete.-that-s-wrong/|title=article|date=2019-07-15|website=nouvelles.umontreal.ca|language=en|access-date=2020-01-04}}{{Cite web|url=https://nouvelles.umontreal.ca/en/article/2019/11/14/sex-and-gender-in-science-why-they-matter/|title=Sex and gender in science: why they matter|last=|first=|date=2019-07-15|website=nouvelles.umontreal.ca|language=en|url-status=live|archive-url=https://web.archive.org/web/20200901012256/https://nouvelles.umontreal.ca/en/article/2019/11/14/sex-and-gender-in-science-why-they-matter/ |archive-date=2020-09-01 |access-date=2020-01-04}}{{Cite journal|last1=Tannenbaum|first1=Cara|last2=Greaves|first2=Lorraine|last3=Graham|first3=Ian D.|date=December 2016|title=Why sex and gender matter in implementation research|journal=BMC Medical Research Methodology|language=en|volume=16|issue=1|page=145|doi=10.1186/s12874-016-0247-7|issn=1471-2288|pmc=5084413|pmid=27788671 |doi-access=free }}{{Cite web|url=https://www.ctvnews.ca/sports/testosterone-rule-for-female-athletes-is-unscientific-canadian-researcher-says-1.4345189|title=Testosterone rule for female athletes is unscientific, Canadian researcher says|last=Lowrie|first=Morgan|date=2019-03-20|website=CTVNews|language=en|access-date=2020-01-04}}

• Tannenbaum, Cara, Philippe Martin, Robyn Tamblyn, Andrea Benedetti, and Sara Ahmed. "Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial." JAMA Internal Medicine 174, no. 6 (2014): 890-898.
• Tannenbaum, Cara, Julie Clark, Kevin Schwartzman, Sylvan Wallenstein, Robert Lapinski, Diane Meier, and Marjorie Luckey. "Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women." The Journal of Clinical Endocrinology & Metabolism 87, no. 10 (2002): 4431-4437.
• Andersson, Karl-Erik, Christopher R. Chapple, Linda Cardozo, Francisco Cruz, Hashim Hashim, Martin C. Michel, Cara Tannenbaum, and Alan J. Wein. "Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence." Current Opinion in Urology 19, no. 4 (2009): 380-394.
• Tannenbaum, Cara, Amélie Paquette, Sarah Hilmer, Jayna Holroyd-Leduc, and Ryan Carnahan. "A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs." Drugs & Aging 29, no. 8 (2012): 639-658.

{{reflist}}

{{authority control}}

{{DEFAULTSORT:Tannenbaum, Cara}}

Category:Year of birth missing (living people)

Category:Living people

Category:Academic staff of the Université de Montréal

Category:McGill University alumni

Category:Fellows of the Canadian Academy of Health Sciences

Category:Canadian women physicians

Category:Canadian geriatricians

Category:Women geriatricians

Category:21st-century Canadian physicians

Category:Members of the Order of Canada